EP3902917A4 - Compositions et méthodes pour le traitement du cancer - Google Patents

Compositions et méthodes pour le traitement du cancer Download PDF

Info

Publication number
EP3902917A4
EP3902917A4 EP19904756.4A EP19904756A EP3902917A4 EP 3902917 A4 EP3902917 A4 EP 3902917A4 EP 19904756 A EP19904756 A EP 19904756A EP 3902917 A4 EP3902917 A4 EP 3902917A4
Authority
EP
European Patent Office
Prior art keywords
cancer
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19904756.4A
Other languages
German (de)
English (en)
Other versions
EP3902917A2 (fr
Inventor
Vivienne I. Rebel
David J. ELZI
William E. Bauta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioaffinity Technologies Inc
Original Assignee
Bioaffinity Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioaffinity Technologies Inc filed Critical Bioaffinity Technologies Inc
Publication of EP3902917A2 publication Critical patent/EP3902917A2/fr
Publication of EP3902917A4 publication Critical patent/EP3902917A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19904756.4A 2018-12-27 2019-12-23 Compositions et méthodes pour le traitement du cancer Pending EP3902917A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862785592P 2018-12-27 2018-12-27
PCT/US2019/068423 WO2020139866A2 (fr) 2018-12-27 2019-12-23 Compositions et méthodes pour le traitement du cancer

Publications (2)

Publication Number Publication Date
EP3902917A2 EP3902917A2 (fr) 2021-11-03
EP3902917A4 true EP3902917A4 (fr) 2022-11-30

Family

ID=71129313

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19904756.4A Pending EP3902917A4 (fr) 2018-12-27 2019-12-23 Compositions et méthodes pour le traitement du cancer

Country Status (4)

Country Link
EP (1) EP3902917A4 (fr)
CN (1) CN113508175B (fr)
CA (1) CA3163139A1 (fr)
WO (1) WO2020139866A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12305171B2 (en) 2018-12-27 2025-05-20 Bioaffinity Technologies, Inc. Compositions and methods for treating cancer
CA3174172A1 (fr) * 2021-06-28 2023-07-26 Bioaffinity Technologies, Inc. Compositions et methodes de traitement du cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007117657A2 (fr) * 2006-04-07 2007-10-18 The Research Foundation Of State University Of New York Polypeptides du récepteur de la transcobalamine, acides nucléiques et modulateurs associés, procédés d'utilisation associés destinés à moduler la croissance cellulaire et à traiter le cancer et la déficience en cobalamine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239270B1 (en) * 1993-05-24 2001-05-29 Rhone-Poulenc Rorer S.A. Nucleic acids encoding human calcium sensor protein
US20030004311A1 (en) * 1997-06-18 2003-01-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7041490B1 (en) * 1997-11-28 2006-05-09 Serono Genetics Institute, S.A. Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same
WO2001053455A2 (fr) * 1999-12-23 2001-07-26 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides associes
US20080050393A1 (en) * 1998-12-03 2008-02-28 Tang Y Tom Novel nucleic acids and polypeptides
JP4865377B2 (ja) * 2006-03-28 2012-02-01 国立大学法人 新潟大学 ヒトメガリンの測定方法
US9044461B2 (en) * 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
AU2006344331A1 (en) * 2006-06-02 2007-12-13 Human Genetic Signatures Pty Ltd Modified microbial nucleic acid for use in detection and analysis of microorganisms
KR20100015786A (ko) * 2007-03-21 2010-02-12 랩터 파마슈티컬 인코포레이티드 환형의 수용체-연관된 단백질(ｒａｐ) 펩티드
US10113201B2 (en) * 2013-04-05 2018-10-30 The Wistar Institute Of Anatomy And Biology Methods and compositions for diagnosis of glioblastoma or a subtype thereof
EP3325662B1 (fr) * 2015-07-17 2023-08-30 Pacylex Pharmaceuticals Inc. Silençage épigénétique de nmt2
WO2017223273A1 (fr) * 2016-06-22 2017-12-28 President And Fellows Of Harvard College Inhibition de cellules lymphoïdes innées de groupe 3 du côlon

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007117657A2 (fr) * 2006-04-07 2007-10-18 The Research Foundation Of State University Of New York Polypeptides du récepteur de la transcobalamine, acides nucléiques et modulateurs associés, procédés d'utilisation associés destinés à moduler la croissance cellulaire et à traiter le cancer et la déficience en cobalamine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDERSEN RIKKE K. ET AL: "Melanoma tumors frequently acquire LRP2 /megalin expression, which modulates melanoma cell proliferation and survival rates", PIGMENT CELL & MELANOMA RESEARCH, vol. 28, no. 3, 14 January 2015 (2015-01-14), United States, Denmark, pages 267 - 280, XP055968578, ISSN: 1755-1471, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1111/pcmr.12352> DOI: 10.1111/pcmr.12352 *
SHAO-CHIANG LAI ET AL: "Down-regulation of transcobalamin receptor TCblR/by siRNA inhibits cobalamin uptake and proliferation of cells in culture", EXPERIMENTAL CELL RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 317, no. 11, 25 February 2011 (2011-02-25), pages 1603 - 1607, XP028218051, ISSN: 0014-4827, [retrieved on 20110304], DOI: 10.1016/J.YEXCR.2011.02.016 *

Also Published As

Publication number Publication date
WO2020139866A3 (fr) 2020-10-15
CN113508175B (zh) 2025-08-19
EP3902917A2 (fr) 2021-11-03
CN113508175A (zh) 2021-10-15
WO2020139866A2 (fr) 2020-07-02
CA3163139A1 (fr) 2020-07-02

Similar Documents

Publication Publication Date Title
EP3999548A4 (fr) Anticorps dirigés contre la claudine 18 et méthodes de traitement du cancer
EP3585817A4 (fr) Compositions et procédés de traitement du cancer
EP3883580A4 (fr) Méthodes de traitement de cancers
EP4034138A4 (fr) Compositions et procédés pour le traitement de cancers liquides
EP3703711A4 (fr) Compositions et méthodes pour le traitement du cancer avec une immunothérapie anti-ror1
EP3490581A4 (fr) Compositions neuromodulatrices et méthodes associées de traitement du cancer
EP3612222A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3532464A4 (fr) Compositions et procédés pour le traitement du cancer à médiation par l&#39;ezh2
EP3592346A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3600302A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3507360A4 (fr) Compositions et méthodes de traitement d&#39;un cancer déficient en suppresseur de tumeur
EP3484913C0 (fr) Procédés et compositions pour le traitement du cancer
EP3655534C0 (fr) Compositions et procédés de traitement de bêta-hémoglobinopathies
EP3902532A4 (fr) Associations immuno-modulatrices et procédés destinés au traitement de cancers
EP4003351A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3576792A4 (fr) Méthodes, compositions et trousses pour le traitement du cancer
EP3528798A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3965896A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3541421A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3534914C0 (fr) Compositions de zinc-gamma-pga et procédés de traitement du cancer
EP3600329A4 (fr) Compositions et procédés de traitement du cancer
EP3600291A4 (fr) Compositions et méthodes de traitement des synucléinopathies
EP3468546A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3429613A4 (fr) Compositions et méthodes de traitement de cancers
EP3585398A4 (fr) Compositions et méthodes pour le traitement du cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210727

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20221027

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/713 20060101ALI20221021BHEP

Ipc: C07K 14/705 20060101ALI20221021BHEP

Ipc: C12N 15/113 20100101AFI20221021BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230508

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250305